ClinicalTrials.gg
RecruitingNCT05631405Updated Jun 16, 2026

Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)

An interventional study of Dexamethasone and Placebo in Severe Dengue, sponsored by Chulalongkorn University. Recruiting at 2 sites in Thailand. Open to participants aged 7 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Chulalongkorn University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
7 Years to 99 Years
Sex
All
01

Study summary

The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.

02

Conditions studied

  • Severe Dengue

Browse trials for

Keywords

  • Severe Dengue
  • Dexamethasone
  • Steroid
03

In context

Severe Dengue

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's planned enrollment of 200 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 323 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test)
  • And still in febrile phase (Body temp>37.5 C)
  • Shock : Sys\<90mmHg or Narrow PP (\<20mmHg) orTachycardia (pulse>100/min) with Hematocrit decreased ≥20 %
  • Fluid accumulation and respiratory distress
  • Severe bleeding
  • Severe organ involvement

Exclusion criteria

Exclusion Criteria:

  • Severe dengue> 24 hrs
  • Dengue without warning signs
  • Pregnancy
  • Patient who receieved any within 1 week
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Intervention

    Drug: Dexamethasone

Interventions

  • Patients treated with dexamethasone

  • DrugPlacebo

    Patients treated with placebo

06

What researchers measure

Primary outcomes

  1. Mortality

    The use of steroids in dengue will reduce mortality in rate

    Time frame: 28 days

Secondary outcomes

  1. Length of hospital stay

    The use of steroids in dengue will reduce Length of hospital stay in day

    Time frame: 28 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Nov 30, 2022
StartActual
Oct 16, 2022
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 31, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05631405
Responsible party
Nattachai Srisawat ,M.D. (Principal investigator, Chulalongkorn University) — Principal investigator
First posted
Nov 30, 2022
Start date
Oct 16, 2022
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion